Covid-19: Screening without scrutiny, spending taxpayers’ billionsBMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4487 (Published 19 November 2020) Cite this as: BMJ 2020;371:m4487
- Kamran Abbasi, executive editor
Follow Kamran on Twitter @KamranAbbasi
Mass testing is a euphemism for population screening. A range of experts who care about screening for the right reasons, in the right contexts, with the right tests, and with the correct follow-up, are in no doubt.
Mike Gill and Muir Gray (who was knighted for his work on national screening programmes) insist the Liverpool mass testing pilot must be stopped.1 It is screening by the back door, bypassing appraisal by the UK’s National Screening Committee. The lateral flow test being used is of doubtful value, with a high false negative rate. Although the false positive rate is small it is still a problem in a low prevalence setting.
Angela Raffle, another leading expert on screening, argues that Operation Moonshot takes us back to the paternalistic 1960s, ignores data protection and privacy laws, and is potentially in breach of the Declaration of Helsinki.23 Bing Jones and colleagues say we must stop being polite about “test and trace,” with its narrow focus on testing, costing billions of pounds to the taxpayer.4
Instead of listening, inviting scrutiny, or waiting for the results of its Liverpool pilot, England’s Department of Health and Social Care is rushing out mass testing to 67 more areas.5 The government is using the covid-19 pandemic to cut corners in procurement and award contracts without transparency, finds the National Audit Office, which reviewed £18bn of contracts awarded in the first wave.6 Companies are being prioritised solely on the recommendation of officials and politicians. An emergency is no excuse for this bad practice, and the Public Accounts Committee says the NAO’s findings are likely to be the tip of the iceberg.
Some might say The BMJ is playing politics, as one reader does.7 But The BMJ’s duty is to patients and the public, especially the most vulnerable,8 and not to any political party or any company’s shareholders. It is inevitable that whichever party is in power is held to account. Stephen Armstrong’s BMJ investigation into the recent award of a £75m contract for an antibody test that works less well than claimed, even for surveillance purposes, shows why that scrutiny is essential.91011 The government’s pandemic response is suppressing science for political and financial gain.12
To echo Stephen Sondheim, “You take one road, you try one door, there isn’t time for any more.”13 That road may lead to a vaccine.1415 But the road is muddier than it needed to be, steeper and more tortuous, and littered with premature deaths and long covid. The government is now embarking on a £100bn mass testing programme that the experts say is fatally flawed, founded on inadequate diagnostic tests, not backed up by adequate contact tracing and isolation, with a track record of maladministration. Among these failures, perhaps the gravest error is an arrogant disregard for scrutiny.